ABRYSVO
Biological
PFIZER INC.
Total Payments
$64.9M
Transactions
13,025
Doctors
6,076
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $22.9M | 7,547 | 4,576 |
| 2023 | $42.0M | 5,478 | 2,289 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $63.4M | 4,062 | 97.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $656,272 | 224 | 1.0% |
| Consulting Fee | $328,898 | 46 | 0.5% |
| Travel and Lodging | $227,199 | 423 | 0.4% |
| Food and Beverage | $226,847 | 8,264 | 0.3% |
| Honoraria | $8,160 | 6 | 0.0% |
Payments by Type
Research
$63.4M
4,062 transactions
General
$1.4M
8,963 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | PFIZER INC. | $41.4M | 0 |
| A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | PFIZER INC. | $7.4M | 0 |
| A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE | PFIZER INC. | $6.7M | 0 |
| RSV OLDER ADULT MULTISPECIMEN STUDYNORTON | PFIZER INC. | $4.1M | 0 |
| A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE | PFIZER INC. | $1.4M | 0 |
| PREVENTION OF OUTPATIENT ACUTE RESPIRATORY ILLNESS IN INFANTS AND DESCRIPTIVE EPIDEMIOLOGY OF RSV IN INFANTS AND THEIR MOTHERS | PFIZER INC. | $907,177 | 0 |
| A POSTMARKETING SAFETY STUDY TO EVALUATE THE SAFETY OF RESPIRATORY SYNCYTIAL VIRUS VACCINE ABRYSVO EXPOSURE DURING PREGNANCY IN AN INTEGRATED HEALTHCARE SYSTEM IN THE UNITED STATES | PFIZER INC. | $618,067 | 0 |
| UWASHRSV SEROEPIDEMIOLOGY AND ANTIBODY TRANSFER AMONG PREGNANT WOMEN AND PRETERM INFANTS | PFIZER INC. | $385,000 | 0 |
| DETERMINING RSV BURDEN AND OUTCOMES IN PREGNANT WOMEN AND OLDER ADULTS REQUIRING HOSPITALIZATION | PFIZER INC. | $375,000 | 0 |
| RSV NEUTRALIZATION STUDIES FOR MATERNAL INFANT STUDY | PFIZER INC. | $109,575 | 0 |
| PEDIATRIC RSV SEROEPIDEMIOLOGY STUDY | PFIZER INC. | $50,000 | 0 |
| RESPIRATORY SYNCYTIAL VIRUS RSV SEROEPIDEMIOLOGY STUDY IN PRETERM INFANTS IN GUATEMALA | PFIZER INC. | $40,000 | 0 |
| RSV VACCINE PROT SUBUNIT PREF 2V CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $23,960 | 7 |
| RSV VACCINE PROTSUBUNIT PREF 2V CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $19,740 | 7 |
| ABRYSVO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,400 | 2 |
| RSV VACCINE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,400 | 1 |
| PF06928316 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $620.00 | 1 |
Top Doctors Receiving Payments for ABRYSVO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Luman Hughes | — | Walnut Creek, CA | $63.4M | 4,045 |
| , M.D | Infectious Disease | Atlanta, GA | $203,526 | 2 |
| , RN, MSN, PHD | Family | Louisville, KY | $146,898 | 203 |
| , MD | Pediatric Infectious Diseases | Aurora, CO | $97,884 | 45 |
| , M.D | Pediatric Infectious Diseases | Corpus Christi, TX | $57,428 | 47 |
| , M.D | Infectious Disease | Sylmar, CA | $57,063 | 75 |
| , MD | Pediatrics | Memphis, TN | $53,449 | 15 |
| , MD | Pediatric Infectious Diseases | Memphis, TN | $47,901 | 12 |
| , MD | Pediatric Infectious Diseases | Carmel, IN | $40,886 | 38 |
| , M.D | Infectious Disease | Stratford, CT | $36,449 | 31 |
| , D.O | Infectious Disease | Wynnewood, PA | $26,491 | 28 |
| , MD | Infectious Disease | Louisville, KY | $25,859 | 5 |
| , MD | Infectious Disease | Dallas, TX | $25,447 | 22 |
| , MD | Maternal & Fetal Medicine | Detroit, MI | $23,869 | 10 |
| , MD | Infectious Disease | Rochester, NY | $22,529 | 13 |
| , MD | Internal Medicine | Sacramento, CA | $22,020 | 30 |
| , M.D | Pulmonary Disease | Ponce, PR | $21,238 | 15 |
| Janet Englund | Pediatric Infectious Diseases | Seattle, WA | $19,699 | 6 |
| , M.D | Obstetrics & Gynecology | Leesburg, VA | $19,605 | 31 |
| , M.D | Obstetrics & Gynecology | New York, NY | $17,410 | 10 |
| , M.D | Obstetrics & Gynecology | Omaha, NE | $17,323 | 24 |
| , MD | Family Medicine | Buffalo, NY | $15,814 | 17 |
| , MD | Specialist | Flemington, NJ | $14,304 | 11 |
| , MD | Infectious Disease | Rochester, NY | $13,387 | 6 |
| , MD | Pediatrics | Pittsburgh, PA | $11,733 | 9 |
Ad
Manufacturing Companies
- PFIZER INC. $64.8M
- PFIZER INTERNATIONAL LLC $74,036
- PFIZER CHILE S.A. $2,000
- PBG PUERTO RICO LLC $20.14
Product Information
- Type Biological
- Total Payments $64.9M
- Total Doctors 6,076
- Transactions 13,025
About ABRYSVO
ABRYSVO is a biological associated with $64.9M in payments to 6,076 healthcare providers, recorded across 13,025 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2023 to 2024. In 2024, $22.9M was paid across 7,547 transactions to 4,576 doctors.
The most common payment nature for ABRYSVO is "Unspecified" ($63.4M, 97.8% of total).
ABRYSVO is associated with 17 research studies, including "A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS" ($41.4M).